Geisinger, Purdue Pharma team up to study effects of Apple Watch for treating chronic pain patients

Danville, Penn.-based Geisinger Health System and Stamford, Conn.-based Purdue Pharma began enrolling patients in their clinical trial, "Effect of Wearable Health Technology on the Treatment of Patients with Chronic Pain at Geisinger."

The study will evaluate how wearable health technology — specifically the Apple Watch — benefits chronic pain patients treated at a specialty clinic. The watch will integrate Geisinger's EHR and measure patients' physical activity, reported pain, disability, sleep quality, depression, and medication use and heart rate. It will also guide patients toward non-pharmaceutical treatment alternatives like stretching and mindfulness.

"The goal of this technology is to improve patient function and quality of life while reducing the need for analgesic medications. It provides objective measures of numerous aspects of pain, function and treatment effectiveness so that information can be gathered for the patient and the healthcare provider in between visits," said Tracy Mayne, PhD, head of medical affairs strategic research at Purdue Pharma.

More articles on health IT:

Epic tool helps U of Maryland Medical System reduce CT angiogram orders by 10%

GAO: 24 agencies have weakness in core IT areas

4 thoughts on 'disruption' in healthcare from NewYork-Presbyterian CIO Daniel Barchi

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars